CRECON MEDICAL ASSESSMENT INC has become the member of MINERVA, an international consortium of leaders in the field of health economics and outcomes. We will plan further globalization by participation in MINERVA and support an action to evaluate cost-effectiveness in the healthcare to both domestic and international clients in the pharmaceutical and medical device industries.
To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.
The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.
Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.
We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).